Targeting SOX2 as a Therapeutic Strategy in Glioblastoma

Laura Garros-Regulez1†, Idoia Garcia1,2†, Estefania Carrasco-Garcia1, Aquilino Lantero3, Paula Aldaz1, Leire Moreno-Cugnon1, Olatz Arrizabalaga1, Jose Undabeitia4, Sergio Torres-Bayona4, Jorge Villanua1,4, Irene Ruiz1,4, Larraitz Egaña1,4, Nicolas Sampron1,4* and Ander Matheu1,2,4*

1Cellular Oncology Group, Department of Oncology, Biodonostia Institute, San Sebastian, Spain, 2IKERBASQUE Foundation, Bilbao, Spain, 3Opioid Research Group, Department of Pharmaceutical Chemistry, University of Innsbruck, Innsbruck, Austria, 4Neuro-Oncology Committee, Donostia Hospital, San Sebastian, Spain

Glioblastoma is the most common and malignant brain cancer in adults. Current therapy consisting of surgery followed by radiation and temozolomide has a moderate success rate and the tumor reappears. Among the features that a cancer cell must have to survive the therapeutic treatment and reconstitute the tumor is the ability of self-renewal. Therefore, it is vital to identify the molecular mechanisms that regulate this activity. Sex-determining region Y (SRY)-box 2 (SOX2) is a transcription factor whose activity has been associated with the maintenance of the undifferentiated state of cancer stem cells in several tissues, including the brain. Several groups have detected increased SOX2 levels in biopsies of glioblastoma patients, with the highest levels associated with poor outcome. Therefore, SOX2 silencing might be a novel therapeutic approach to combat cancer and particularly brain tumors. In this review, we will summarize the current knowledge about SOX2 in glioblastoma and recapitulate several strategies that have recently been described targeting SOX2 in this malignancy.

Keywords: SOX2, glioblastoma, tumor-initiating cells, temozolomide resistance, glioma stem cells, self-renewal inhibition

SOX2

Sex-determining region Y (SRY)-box (SOX) factors are a family of transcriptional regulators that carry out important functions during embryonic development and which are key components for the maintenance of the stem cells in adult tissues. This family of transcription factors is characterized by a conserved high mobility group (HMG) DNA-binding domain and is composed of 20 members divided into 8 groups (from A to H), based on their HMG sequence identity (1). Members within a subfamily conserve at least 80% identity in their HMG-domain, in addition to sharing other well-conserved regions. Moreover, members from the same group might have overlapping expression patterns, share biochemical properties, and perform synergistic or redundant functions. By contrast, members from different subgroups usually develop different functions (2).

SOX2 is a member of the SOXB1 group (together with SOX1 and SOX3), which is required for the maintenance of the embryo before implantation. SOX2 has a role in cell fate and maintenance of the progenitors's identity during embryogenesis. It is also important for tissue homeostasis and regeneration by maintaining stem cell activity in several compartments, particularly in the central nervous system (CNS), in adults (3). During recent years, several studies have demonstrated the impact of SOX2 deregulation in a wide variety of human diseases. A heterozygous inactivation of SOX2 causes syndromic microphthalmia-3 (MCOPS3), a genetic disease characterized by anophthalmia,
microphthalmia mild hypopituitarism, and sometimes learning difficulties, convulsions, motor dysfunctions, and growth problems (4). On the contrary, SOX2 upregulation has been linked to the development and maintenance of several types of cancers (3, 5–7).

**GLIOBLASTOMA**

Tumors of the CNS form a heterogeneous group of diseases that comprise less than 2% of the total number of cancer cases. Every year in the world, ~350,000 people are diagnosed with gliomas, making it the most common primary brain tumor (8). According to clinical and histopathological characteristics, WHO classified them by four grades of malignancy: pylocitic astrocytoma (grade I); diffuse astrocytoma (grade II); anaplastic astrocytoma (grade III), and glioblastoma multiforme (GBM, grade IV). GBM is the most common, malignant, and lethal glioma subtype in adults accounting for 12–15% of all brain tumors and about 50% of gliomas. The incidence ranges from 1 to 5 cases per 100,000 people per year, with an average patient survival of around 15 months (8). This prognosis identifies this type of tumor as one of the most aggressive and fatal cancers overall. According to the clinical presentation, there are two main GBM subtypes: primary or de novo GBM and secondary GBM. Primary tumors, the most common form, typically appear in older patients without any prior clinical or histological evidence of a lower grade precursor lesion and they have an aggressive clinical course. Secondary tumors are more frequent in younger people and they progress from a previous lower grade glioma with a less aggressive clinical course (9). Genetic and transcriptomic expression studies have allowed a more detailed molecular classification identifying four GBM subtypes: (i) classical, with EGFR amplification and overexpression, CDKN2A and PTEN deletion, NES overexpression and activation of NOTCH and SHH signaling pathways; (ii) mesenchymal, with loss of NF1, TP53, and PTEN, overexpression of MET, CHIL3L1, CD44, and MERTK, and activation of the TNF and NF-kB pathways; (iii) proneural, with PDGFR amplification, loss or mutation of IDH1, PIK3K, TP53, CDKN2A, and PTEN, and activation of HIF, PI3K, and PDGFR pathways; and (iv) neural, with EGFR amplification and overexpression, and expression of neuronal markers, such as NEFL, SYT1, and/or GABRA1 (10). Different subtypes are associated with variable prognosis and response to therapy, and this heterogeneity and this therapy resistance are likely the main characteristics responsible for the glioblastoma patients’ dismal outcome.

The cancer stem cell (CSC) theory postulates a hierarchically organized system in opposition to the stochastic model of tumor growth. The CSC model suggests that only a small group of cells have quiescence and self-renewal capacity within the tumor bulk, and that those are responsible for tumor maintenance and recurrence (11). Nowadays, there is a lot of evidence that supports the existence of CSCs in GBM, called glioma stem cells (GSC), and their relevance in the etiology of GBM. Several groups have been able to isolate GSCs from patient-derived tumors and multiple experimental data have shown that these cells are responsible for glioblastoma initiation and maintenance (12, 13), as well as for recurrence and chemoresistance (14–16). Moreover, there are different explanations for their origin. One of them proposes that neural stem cells (NSCs) undergo malignant transformation while retaining stem cell features. Indeed, inactivation of TP53, INK4a/ARF locus, PTEN, and NF1 tumor suppressors or activation of EGFR/PDGFR/P13K oncogenic pathways in NSCs induces high-grade gliomas (17). Similarly, transient amplifying progenitors have been also shown as GSCs and the cell of origin of GBM (18).

Another theory claims that more mature or differentiated cells are reprogrammed and form GSCs and high-grade gliomas. Indeed, several mutations in astrocytes, oligodendrocyte progenitors, or in neurons are sufficient to confer stem cell properties during neoplastic transformation (19, 20). Therefore, in order to establish efficient treatments that can induce a long-lasting clinical response in GBM, it is important to develop strategies that can specifically target GSCs (Figure 1A). CSCs, including GSCs, achieve self-renewal through asymmetric division, in which one daughter cell retains the self-renewal ability, and the other is directed to differentiation. Moreover, heterogeneous tumor cell populations and their respective cell division mode have been shown to confer differential sensitivity to therapy in brain tumors (21). Therefore, modulation of asymmetric and symmetric division of GSCs may provide novel strategies for targeting differentially the GSC and the bulk tumor mass. Several drugs and approaches have been postulated (22) to directly target the GSCs population and/or the molecular mechanisms underlying their regulation. In this review, we focused our attention on targeting SOX2 gene.

**SOX2 ACTIVITY AND GBM**

Several studies have identified an overexpression of SOX2 in GBM patient samples. It was first found elevated in 90% of human biopsies studied at the mRNA and protein level in 2007. This research also showed that SOX2 expression was restricted to the nucleus (23). Since then, overexpression of SOX2 (with varying percentages of positive cases) was observed in several different and independent cohorts (16, 24–27). Importantly, high levels of SOX2 have been associated with tumor aggressiveness and worse prognosis (28, 29). Moreover, several groups, including ours, identified SOX2 enrichment in the undifferentiated GSC populations and demonstrated that SOX2 possesses an important role in the maintenance of GSCs. Indeed, downregulation of SOX2 through RNA interference strategies in GSCs impairs proliferation and their ability to form tumors in vivo (25, 30–32). Additionally, silencing of SOX2 leads to reduced migration and invasion capabilities (25, 33), while it increases senescence and produces an arrest of the cell cycle in G0/G1 (16, 34). The impact of SOX2 in glioblastoma cells has been further substantiated with overexpression studies. Indeed, ectopic elevation of SOX2 increases the capacity of invasion and migration (25), in addition to cell proliferation and self-renewal activity in conventional glioma cell lines (16). In agreement with this last function, SOX2 is one of the transcription factors, together with POU3F2, OLG2, and SALL2, which is sufficient to reprogram differentiated glioma cells into induced GSCs, similar to GSCs obtained from human biopsies (35). Altogether these data show that glioma cells have a dependence on SOX2 to maintain their tumorigenic activity with GSCs displaying high levels of SOX2.
They also demonstrate that SOX2 possesses an important role in the maintenance of GSCs.

In regard to a putative role of SOX2 controlling cell division modes, a recent work showed that the inhibition of the FACT chaperone complex in GSCs promotes their asymmetrical division in a process that involves SOX2 downregulation (36). In line with these results, other authors found that the knockdown of HMGAI, a chromatin structure regulator, not only in GSCs but also in colon CSCs, induces an asymmetric division together with a decrease in SOX2 expression (37, 38). These works suggest that SOX2 action in the maintenance of undifferentiated GSCs could rely on effects promoting symmetrical in addition to the expected asymmetrical division. Importantly, these results support a hierarchical model of glioma cells controlled by SOX2 expression, which brings up the idea to target SOX2 or to find downstream targetable genes as a strategy to eliminate GSCs and subsequently the tumor.

**UPSTREAM REGULATION OF SOX2**

The regulation of SOX2 is a complex network of transcriptional, post-transcriptional, and post-translational regulators (Table 1). Some of these regulators are altered in GBM and lead to the overexpression of SOX2. Four main signaling pathways are involved in SOX2 expression, including TGF-β, SHH, EGFR, and FGFR. All these signaling pathways are aberrantly activated in GBM, which leads to the maintenance of the tumor at least in part through SOX2 factor overexpression. The inhibition of TGF-β signaling decreases the tumorigenicity of GSCs by the suppression of SOX2 activity (31). SOX2 function is also mediated by other members of the SOX family, such as SOX4, acting downstream of the TGF-β signaling pathway, and forming a complex with OCT4 at the SOX2 promoter (31, 39). SHH pathway is initiated with the binding of SHH ligand to PTCH receptor, causing the activation of SMO. Active SMO will activate GLI1/2, which then translocates into the nucleus and activates SOX2. The regulation of SOX2 by SHH occurs in neural and brain stem cells (40, 41), and the pharmacological inhibition of these pathways silenced SOX2 expression and impaired glioma cells’ tumorigenic activity (16). The FGFR pathway regulates SOX2 expression through two main signaling cascades: (i) MEK/ERK and (ii) PI3K/AKT/mTOR, two signaling pathways activated in GBM, and whose suppression leads to the inhibition of tumorigenesis and self-renewal of GSCs (42). The MEK/ERK pathway regulates the expression of SOX2 through the final phosphorylation of ERK, which translocates into the nucleus and activates the transcription of SOX2. The PI3K/AKT/mTOR pathway regulates positively the expression of SOX2 through the cascade: (i) MEK/ERK and (ii) PI3K/AKT/mTOR, two signaling pathways activated in GBM, and whose suppression leads to the inhibition of tumorigenesis and self-renewal of GSCs (42).

**TABLE 1 | Summary of relevant findings of SOX2 in glioblastoma.**

| Year | Finding | Reference |
|------|---------|-----------|
| 2007 | SOX2 is overexpressed in human glioma samples | Schmitz et al. (23) |
| 2009 | Genetic SOX2 silencing impairs GSCs activity | Gangemi et al. (30) |
| 2011 | Identification of SOX2 downstream targets in GBM with miRNA145–SOX2 feedback loop | Fang et al. (49) |
| 2011 | Genetic and epigenetic regulation of SOX2 in GBM samples | Alonso et al. (25) |
| 2011 | Identification of SOX2 as a target for combination treatments with tyrosine-kinase inhibitors | Hägerstrand et al. (32) |
| 2011 | Identification of SOX2 downstream of TGF-β signaling in GSCs | Ikushima et al. (31) |
| 2014 | Elevated SOX2 promotes dedifferentiation and acquisition of GSC characteristics in GBM cells | Suvà et al. (35) |
| 2007 | First results supporting SOX2 mediated and immunotherapy in mouse models and human samples | Schmitz et al. (23) |
| 2014 | SOX2 induces chemoresistance, which is inhibited by rapamycin | Garros-Regulez et al. (16) |
a frequent mutant in GBM that leads to the activation of pro-oncogenic signaling in GBM. Indeed, the expression of EGFRvIII positively correlates with the expression of SOX2 and is associated with an enhanced self-renewal ability and tumor-initiating activity (43). This correlation has demonstrated that it is carried out by the axis EGFRvIII–STAT3–PEDF–Notch (44).

SOX2 can also be regulated via post-translational modifications, such as ubiquitination, phosphorylation, and acetylation. Acetylation and phosphorylation enhance the export of SOX2 to the cytoplasm and inhibit the ability to bind DNA in embryonic stem cells (45, 46). By contrast, the phosphorylation of SOX2 by AKT stabilizes the protein and enhances the transcriptional activity of SOX2 (47). However, the function of these modifications in GSCs’ activity remains elusive.

Additionally, SOX2 genetic amplification and promoter DNA hypomethylation has been identified in a set of GBM patients, further expanding the mechanism responsible for SOX2 upregulation in glioblastoma samples and GSCs (25). Moreover, the regulation of SOX2 through different miRNAs, including miRNA21 or miRNA145, has been described in glioma cells, with this axis having relevant functions in GSCs’ activity and in the clinic (29, 48).

**DOWNSTREAM REGULATION OF SOX2**

Several studies have started to characterize downstream targets of SOX2 in glioblastoma. A study of Fang et al. identified SOX2 downstream targets by ChIP-seq and microarray analyses in the LN229 glioma cell line. They found 4,883 SOX2 binding regions in the GBM cancer genome. Moreover, they detected 489 genes whose expression was altered with SOX2 inhibition, including additional SOX family members, cytokines, or BEX members with tumor suppressor activity in glioblastoma. They also identified 105 pre-miRNAs (corresponding to 95 mature miRNAs) that were differentially expressed in SOX2 knockdown glioblastoma cells. Among them, they observed that miRNA145 and SOX2 form a double-negative feedback loop in GBM cells (48), demonstrating that the relationship between SOX2 and miRNA is bidirectional. We have recently observed that several oncogenic SOX2 functions are mediated by SOX9, another member of the SOX family (16), which also carries out important functions in GSC regulation and glioblastoma (26). This regulation occurs at post-transcriptional level (16). Additionally, specific phenotypes associated with SOX2 have been linked to different genes and signaling pathways. Indeed, SOX2-regulated migratory and invasive capacities are mediated by RhoA-dependent pathway and focal adhesion kinase (FAK) signaling, whereas proliferation is mediated by CYCLIN D1 expression (34). WNT signaling pathway, self-renewal, and retinoic acid associated genes are within the genes involved in SOX2-mediated glioma cell plasticity and astrocytic differentiation (49).

**THERAPEUTIC APPROACHES TOWARD SOX2 REDUCTION IN GBM**

The current chemotherapeutic agent for newly diagnosed GBM is temozolomide (TMZ), which extends patient survival from 12 to 15 months (50). A role for SOX2 in TMZ chemoresistance has been deciphered during recent years. Thus, cells with elevated SOX2 expression are more resilient to TMZ, whereas its inhibition sensitizes glioma cells to this agent (16). This cellular finding is correlated with clinical information. High levels of SOX2 have been included as a marker of the proneural subtype, which has been shown to be the most resistant subgroup to current therapeutic radio- and chemotherapy treatment (10). The involvement of SOX2 in chemoresistance has been further substantiated through different mechanisms. The inhibition of SOX2 by miRNA145 decreases the chemoresistance of GSCs and increases the sensitivity to radiation and TMZ (51). The overexpression of ID-4 suppresses the expression of miRNA9, that can repress SOX2, leading to an increase in the SOX2 expression. SOX2 induction enhances the ATP-binding cassette (ABC) transporters, ABCG2 and ABCG2, through direct transcriptional regulation. The activation of ABC transporters confers chemoresistance to GSCs (52). These facts together with its prominent role in the regulation of GSCs suggest that SOX2 might be a key responsible factor for resistance to current chemotherapy and postulate that targeting its activity may offer a novel, attractive therapeutic approach to treat glioblastoma patients.

Several strategies are starting to use SOX2 directly or indirectly to target GSCs (Figure 1B). PDGFR signaling has been involved in glioblastoma biology through studies based on analyses of human tumor tissue, cultured glioblastoma cells, and mouse glioblastoma models (22). Similarly, IGF1-R signaling has been described in glioblastoma, and findings from preclinical studies suggest favorable combination effects when IGF1-R inhibitors have been combined with other receptor tyrosine-kinase (RTK)-targeting agents. Interestingly, a combination therapy with PDGF and IGF1 receptor inhibitors (imatinib and NVP-AEW541) produces a significant tumor growth reduction through SOX2 downregulation and GSC sensitization (32).

Rapamycin is an allosteric inhibitor of mTOR, which has been shown to dramatically reduce the self-renewal and tumorigenic activity of glioma cells and GSCs (53). In agreement with these results, several phase I and II clinical trials, with some of its rapalogs, such as everolimus or temsirolimus, alone or in combination, showed radiographic and symptomatic evidence of improvement in delaying tumor progression without provoking high toxicity in patients with newly diagnosed or recurrent glioblastoma (54). It has recently been demonstrated that mTOR regulates the expression of SOX2. Genetic mTOR silencing or pharmacological treatment with rapamycin markedly reduced SOX2 levels in glioma cells (16). Interestingly, the same work showed that the combination of rapamycin and TMZ was more efficient and displayed increased cytotoxicity in cells with high endogenous SOX2 levels (16). Cycloamine, an inhibitor of the SHH pathway, was also proved effective in reducing SOX2 expression and inducing cytotoxicity in *in vitro* studies, but unlike rapamycin, its combination with TMZ did not increase the sensitivity of glioma cells to chemotherapy (16). Furthermore, several studies have demonstrated the capability of the GSCs to transdifferentiate into tumor-derived vascular endothelial and mural-like cells in a VEGF-independent manner, making the tumor resistant to anti-vascular therapy (55, 56).
transdifferentiation relies on high levels of NESTIN and CD133 stem markers; however, SOX2 has not been evaluated. It would be of interest to determine the role of SOX2 in transdifferentiation and if knocking down its expression levels is sufficient to prevent the process.

Alternative treatments are arising using SOX2 protein as the principal target of new therapies. Immunotherapy represents a promising treatment option to improve the clinical outcome of patients suffering from GBM. In 2014, Dr Nicolis’ group did transplants of GSCs in mice brains using peptide vaccination against SOX2. Peptide vaccination alone increased the mice’ survival and the vaccination in combination with the current treatment with TMZ doubled the mice’ survival time (41). Before, Schmitz and coworkers identified SOX2 as a glioma-associated antigen abundantly and specifically overexpressed in glioma cells. In addition, they identified an immunogenic HLA-A*0201-restricted T-cell epitope derived from SOX2 that effectively activated tumor-directed cytotoxic T lymphocytes (23). These results highlight the suitability of SOX2 for a novel strategy based in immunotherapy in monotherapy or in combination with current therapies for the treatment of glioblastoma patients.

The use of miRNA delivery could be another therapy linked to SOX2 for cancer cells in the brain. As described above, miRNA145 is associated with SOX2. Interestingly, miRNA145 delivery in GSCs and in xenograft studies in vivo demonstrated the ability to suppress the tumorigenicity by direct downregulation of SOX2 protein with cells becoming more sensitive to chemotherapeutic agents, such as TMZ or cisplatin (51). The promising therapeutic prospect of miR-145 might improve current cancer treatments, especially for those tumors that have developed a resistance to conventional therapeutic methods. However, a note of caution needs to be included since the use of viral vectors for gene delivery may be accompanied by several problems, including an immune response.

CONCLUDING REMARKS

Glioblastoma is the most common and malignant adult primary brain tumor with a dismal patient prognosis. It is characterized by presenting significant heterogeneity at the genetic, molecular, cellular, and morphological level, which severely affects clinical practice. Tumor bulk is formed by differentiated cells targetable with chemo- and radiotherapy and GSCs, which need to be eradicated in order to achieve effective therapeutic response.

Sex-determining region Y (SRY)-box 2 transcription factor is important during embryonic development and for the maintenance of stem cell properties of the CNS in adult and aged stages (3, 57, 58). It is also a key regulator of stemness in CSCs and its biological function has been widely described in GBM, associated with stemness activity and a poor clinical outcome (Table 1). Therefore, SOX2 is a strong molecular candidate to be targeted in glioblastoma samples and the potential benefit of SOX2 targeting in the scenario of such a lethal tumor is not negligible. However, a point to take into account with regard to SOX2 targeting for GBM treatment is that other SOX2 expressing cell populations as astrocytes, which develop relevant roles in neurogenesis, could be susceptible to the treatments. The consequences of this must be evaluated and other molecules acting downstream of SOX2, and more specific of GSCs, should be identified and considered as targets.

Transcriptional regulation and/or post-transcriptional suppression of SOX2 through miRNA regulation are promising approaches. There are also encouraging results with SOX2 immunotherapy or combining tyrosine-kinase and IGF1 inhibitors. These results show the preclinical proof of concept that silencing SOX2 activity is an effective strategy in glioblastoma. More solid and extensive preclinical results and clinical trials with the postulated combination of therapies in glioblastoma patients whose biopsies express elevated SOX2 are needed to establish their clinical impact.

AUTHOR CONTRIBUTIONS

LG-R and IG, first authors of the review, wrote most of the review. NS and AM, senior authors, designed the review, directed the work, and wrote the manuscript. The additional authors suggested ideas and revised the manuscript.

FUNDING

LG-R, LM-C, and OA are recipients of a predoctoral fellowship from the Department of Education, Universities and Research of the Basque Government. PA is in receipt of a predoctoral fellowship from the Spanish Association Against Cancer (AECC Gipuzkoa). This work was supported by grants from the Spanish Ministry of Economy and Competition (CP10/00539, PI13/02277) and the European Union (Marie Curie CIG 2012/712404, REFBI013/BIOD/009 and 011) for AM.

REFERENCES

1. Kamachi Y, Kondoh H. Sox proteins: regulators of cell fate specification and differentiation. Development (2013) 140:4129–44. doi:10.1242/dev.091793
2. Wegner M. All purpose Sox: the many roles of Sox proteins in gene expression. Int J Biochem Cell Biol (2009) 41:381–90. doi:10.1016/j.biocel.2009.07.006
3. Sarkar A, Hochledinger K. The sox family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell Stem Cell (2013) 12:15–30. doi:10.1016/j.stem.2012.12.007
4. Kelberman D, Rizzoti K, Avilion A, Bitner-Glindzicz M, Cianfarani S, Collins J, et al. Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. J Clin Invest (2006) 116:2442–55. doi:10.1172/JCI28658
5. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 41:1238–42. doi:10.1038/ng.665
6. Li H, Collado M, Villasante A, Matheu A, Lynch CJ, Cañamero M, et al. p27(Kip1) directly represses Sox2 during embryonic stem cell differentiation. Cell Stem Cell (2012) 11:845–52. doi:10.1016/j.stem.2012.09.014
7. Carrasco-Garcia E, Santos JC, Garcia I, Brianti M, Garcia-Puga M, Pedrazzoli J Jr, et al. Paradoxical role of SOX2 in gastric cancer. Am J Cancer Res (2016) 6:701–13.
8. Ostrom QT, Baulch L, Davis FG, Deltour I, Fisher JL, Langer CE, et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol (2014) 16:896–913. doi:10.1093/neuonc/nou807
9. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res (2013) 19:764–72. doi:10.1158/1078-0432.CCR-12-3002
or differentiation. *Mol Cell* (2014) 55:537–51. doi:10.1016/j.molcel.2014.06.018

48. Fang X, Yoon JG, Li L, Yu W, Shao J, Hua D, et al. The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis. *BMC Genomics* (2011) 12:11. doi:10.1186/1471-2164-12-11

49. Berezovsky AD, Poisson LM, Cherba D, Webb CP, Transou AD, Lemke NW, et al. Sox2 promotes malignancy in glioblastoma by regulating plasticity and astrocytic differentiation. *Neoplasia* (2014) 16:e119–25. doi:10.1016/j.neo.2014.03.006

50. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* (2005) 352:987–96. doi:10.1056/NEJMoa043330

51. Yang YP, Chien Y, Chious GX, Chergg JY, Wang ML, Lo WL, et al. Inhibition of cancer stem cell-like properties and reduced chemoradiosensitivity of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. *Biomaterials* (2012) 33:1462–76. doi:10.1016/j.biomaterials.2011.10.071

52. Jeon HM, Sohn YW, Oh SY, Kim SH, Beck S, Kim S, et al. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. *Cancer Res* (2011) 71:3410–21. doi:10.1158/0008-5472.CAN-10-3340

53. Arcella A, Biagioni F, Antonietta Oliva M, Bucci D, Frati A, Esposito V, et al. Rapamycin inhibits the growth of glioblastoma. *Brain Res* (2013) 1495:37–51. doi:10.1016/j.brainres.2012.11.044

54. Pachow D, Wick W, Gutmann DH, Mawrin C. The mTOR signaling pathway as a treatment target for intracranial neoplasms. *Neuro Oncol* (2015) 17:189–99. doi:10.1093/neuonc/nou164

55. Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. *Proc Natl Acad Sci U S A* (2011) 108:4274–80. doi:10.1073/pnas.1016030108

56. Scully S, Francescone R, Faubish M, Bentley B, Taylor SL, Oh D, et al. Transdifferentiation of glioblastoma stem-like cells into mural cells drives vasculogenic mimicry in glioblastomas. *J Neurosci* (2012) 32:12950–60. doi:10.1523/JNEUROSCI.2017-12.2012

57. Brazel CY, Limke TL, Osborne JK, Miura T, Cai J, Pevny L, et al. Sox2 expression defines a heterogeneous population of neurosphere-forming cells in the adult murine brain. *Aging Cell* (2005) 4:197–207. doi:10.1111/j.1474-9726.2005.00158.x

58. Carrasco-Garcia E, Arrizabalaga O, Serrano M, Lovell-Badge R, Matheu A. Increased gene dosage of Ink4/Arf and p53 delays age-associated central nervous system functional decline. *Aging Cell* (2015) 14(4):710–4. doi:10.1111/acel.12343

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Garros-Regulez, Garcia, Carrasco-Garcia, Lantero, Aldaz, Moreno-Cugnon, Arrizabalaga, Undabietza, Torres-Bayona, Villanua, Ruiz, Egana, Sampron and Matheu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.